This article was originally published in The Gray Sheet
Executive SummarySecondary offering of 1 mil. shares of common stock grosses approximately $13.3 mil. The vital signs monitoring instrument firm's offering includes 900,000 shares from the company and 100,000 shares from a selling shareholder. Cruttenden Roth and Gerard Klauer Mattison & Co. were underwriters for the offering
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.